Status:
COMPLETED
Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Stomach Cancer
Eligibility:
All Genders
18-79 years
Phase:
NA
Brief Summary
"Mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an agent to increase intestinal motility. Mosapride citrate has been demonstrated in in vitro and in vivo studies ...
Eligibility Criteria
Inclusion
- Patients diagnosed with gastric cancer pathologically before surgery
- Patients who underwent surgical resection (R0 resection)
- Patients with an ASA score of 3 or less
Exclusion
- Patients over 80 years old
- When there are multiple or peritoneal metastases
- Intestinal obstruction before surgery
- When chemotherapy was performed before surgery
- When cancer other than stomach cancer is diagnosed
- If you have a long history of major intra-abdominal surgery or a history of abdominal radiotherapy
- In case of liver failure or kidney failure
- When it is judged that uncontrolled diabetes may affect intestinal function
Key Trial Info
Start Date :
July 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT04493125
Start Date
July 27 2020
End Date
March 30 2021
Last Update
January 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GangnamSeverance Hospital
Seoul, South Korea